PL1679074T3 - Środek terapeutyczny do leczenia chorób zapalnych rogówki i spojówki - Google Patents

Środek terapeutyczny do leczenia chorób zapalnych rogówki i spojówki

Info

Publication number
PL1679074T3
PL1679074T3 PL04793171T PL04793171T PL1679074T3 PL 1679074 T3 PL1679074 T3 PL 1679074T3 PL 04793171 T PL04793171 T PL 04793171T PL 04793171 T PL04793171 T PL 04793171T PL 1679074 T3 PL1679074 T3 PL 1679074T3
Authority
PL
Poland
Prior art keywords
therapeutic agent
ylmethoxy
benzimidazol
thiazolidine
dione
Prior art date
Application number
PL04793171T
Other languages
English (en)
Inventor
M Nakamura
S Hirai
Original Assignee
Santen Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Santen Pharmaceutical Co Ltd filed Critical Santen Pharmaceutical Co Ltd
Publication of PL1679074T3 publication Critical patent/PL1679074T3/pl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/04—Artificial tears; Irrigation solutions
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
PL04793171T 2003-10-24 2004-10-22 Środek terapeutyczny do leczenia chorób zapalnych rogówki i spojówki PL1679074T3 (pl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2003364864 2003-10-24
PCT/JP2004/016063 WO2005039574A1 (ja) 2003-10-24 2004-10-22 角結膜障害の治療剤
EP04793171A EP1679074B1 (en) 2003-10-24 2004-10-22 Therapeutic agent for keratoconjunctive disorder

Publications (1)

Publication Number Publication Date
PL1679074T3 true PL1679074T3 (pl) 2011-05-31

Family

ID=34510137

Family Applications (1)

Application Number Title Priority Date Filing Date
PL04793171T PL1679074T3 (pl) 2003-10-24 2004-10-22 Środek terapeutyczny do leczenia chorób zapalnych rogówki i spojówki

Country Status (16)

Country Link
US (1) US7358255B2 (pl)
EP (1) EP1679074B1 (pl)
JP (1) JP4217832B2 (pl)
KR (1) KR101154175B1 (pl)
CN (1) CN1870997B (pl)
AT (1) ATE490771T1 (pl)
CA (1) CA2543452C (pl)
CY (1) CY1111191T1 (pl)
DE (1) DE602004030470D1 (pl)
DK (1) DK1679074T3 (pl)
ES (1) ES2357801T3 (pl)
PL (1) PL1679074T3 (pl)
PT (1) PT1679074E (pl)
SI (1) SI1679074T1 (pl)
TW (1) TWI343256B (pl)
WO (1) WO2005039574A1 (pl)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20060118520A (ko) * 2003-10-29 2006-11-23 산텐 세이야꾸 가부시키가이샤 각결막장해 치료제
WO2006064825A1 (ja) * 2004-12-14 2006-06-22 Santen Pharmaceutical Co., Ltd. ドライアイ治療剤
EP1964575B1 (en) 2005-11-28 2015-09-23 Senju Pharmaceutical Co., Ltd. Pharmaceutical comprising ppar agonist
DK2348023T5 (da) 2005-12-13 2017-05-15 Incyte Holdings Corp Heteroaryl-substituerede pyrrolo[2,3-b]pyridiner og pyrrolo[2,3-b]pyrimidiner som Janus-kinase-inhibitorer
BRPI0811612A2 (pt) 2007-05-21 2014-11-11 Senju Pharma Co Composições farmacêuticas que contêm agonista ppardelta
RS53245B2 (sr) 2007-06-13 2022-10-31 Incyte Holdings Corp Soli inhibitora janus kinaze (r)-3-(4-(7h-pirolo(2,3-d) pirimidin-4-il)-1h-pirazol-1-il)-3-ciklopentilpropan-nitrila
KR20100137417A (ko) * 2008-02-25 2010-12-30 산텐 세이야꾸 가부시키가이샤 각막 상피 배리어 기능 항진제
CL2009001884A1 (es) * 2008-10-02 2010-05-14 Incyte Holdings Corp Uso de 3-ciclopentil-3-[4-(7h-pirrolo[2,3-d]pirimidin-4-il)-1h-pirazol-1-il)propanonitrilo, inhibidor de janus quinasa, y uso de una composición que lo comprende para el tratamiento del ojo seco.
EP2432472B1 (en) 2009-05-22 2019-10-02 Incyte Holdings Corporation 3-[4-(7h-pyrrolo[2,3-d]pyrimidin-4-yl)-1h-pyrazol-1-yl]octane- or heptane-nitrile as jak inhibitors
AU2010249380B2 (en) 2009-05-22 2015-08-20 Incyte Holdings Corporation N-(hetero)aryl-pyrrolidine derivatives of pyrazol-4-yl-pyrrolo[2,3-d]pyrimidines and pyrrol-3-yl-pyrrolo[2,3-d]pyrimidines as Janus kinase inhibitors
US9249145B2 (en) * 2009-09-01 2016-02-02 Incyte Holdings Corporation Heterocyclic derivatives of pyrazol-4-yl-pyrrolo[2,3-d]pyrimidines as janus kinase inhibitors
SI3354652T1 (sl) 2010-03-10 2020-08-31 Incyte Holdings Corporation Derivati piperidin-4-il azetidina kot inhibitorji JAK1
MY178634A (en) 2010-05-21 2020-10-19 Incyte Corp Topical formulation for a jak inhibitor
US9034884B2 (en) 2010-11-19 2015-05-19 Incyte Corporation Heterocyclic-substituted pyrrolopyridines and pyrrolopyrimidines as JAK inhibitors
JP5917545B2 (ja) 2010-11-19 2016-05-18 インサイト・ホールディングス・コーポレイションＩｎｃｙｔｅ Ｈｏｌｄｉｎｇｓ Ｃｏｒｐｏｒａｔｉｏｎ Ｊａｋ阻害剤としてのシクロブチル置換ピロロピリジンおよびピロロピリミジン誘導体
EA201490042A1 (ru) 2011-06-20 2014-10-30 Инсайт Корпорейшн Азетидинил-фенил-, пиридил- или пиразинилкарбоксамидные производные как ингибиторы jak
TW201313721A (zh) 2011-08-18 2013-04-01 Incyte Corp 作為ｊａｋ抑制劑之環己基氮雜環丁烷衍生物
UA111854C2 (uk) 2011-09-07 2016-06-24 Інсайт Холдінгс Корпорейшн Способи і проміжні сполуки для отримання інгібіторів jak
AR091079A1 (es) 2012-05-18 2014-12-30 Incyte Corp Derivados de pirrolopirimidina y pirrolopiridina sustituida con piperidinilciclobutilo como inhibidores de jak
WO2014078486A1 (en) 2012-11-15 2014-05-22 Incyte Corporation Sustained-release dosage forms of ruxolitinib
KR102366356B1 (ko) 2013-03-06 2022-02-23 인사이트 홀딩스 코포레이션 Jak 저해제를 제조하기 위한 방법 및 중간생성물
PE20220579A1 (es) 2013-08-07 2022-04-20 Incyte Corp Formas de dosificacion de liberacion prolongada para un inhibidor de jak 1
WO2015184305A1 (en) 2014-05-30 2015-12-03 Incyte Corporation TREATMENT OF CHRONIC NEUTROPHILIC LEUKEMIA (CNL) AND ATYPICAL CHRONIC MYELOID LEUKEMIA (aCML) BY INHIBITORS OF JAK1
WO2019113487A1 (en) 2017-12-08 2019-06-13 Incyte Corporation Low dose combination therapy for treatment of myeloproliferative neoplasms
EP4086245A1 (en) 2018-01-30 2022-11-09 Incyte Corporation Processes for preparing intermediates for the synthesis of a jak inhibitor
SG11202009441PA (en) 2018-03-30 2020-10-29 Incyte Corp Treatment of hidradenitis suppurativa using jak inhibitors
US11833155B2 (en) 2020-06-03 2023-12-05 Incyte Corporation Combination therapy for treatment of myeloproliferative neoplasms

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3769066D1 (de) 1986-08-28 1991-05-08 Sanwa Kagaku Kenkyusho Co Hydantoin-derivate zur behandlung von komplikationen bei diabetes.
JP3072227B2 (ja) * 1994-08-01 2000-07-31 株式会社クボタ 田植機の粉粒体供給装置
JP3603129B2 (ja) * 1994-12-28 2004-12-22 株式会社三和化学研究所 糖尿病性角膜症の治療剤
IL118474A (en) 1995-06-01 2001-08-08 Sankyo Co Benzimideol derivatives and pharmaceutical preparations containing them
US6372750B2 (en) 1996-07-01 2002-04-16 Dr. Reddy's Research Foundation Heterocyclic compounds, process for their preparation and pharmaceutical compounds containing them and their use in the treatment of diabetes and related diseases
US6114526A (en) 1996-07-01 2000-09-05 Dr. Reddy's Research Foundation Heterocyclic compounds, process for their preparation and pharmaceutical compositions containing them and their use in the treatment of diabetes and related diseases
US5885997A (en) 1996-07-01 1999-03-23 Dr. Reddy's Research Foundation Heterocyclic compounds, process for their preparation and pharmaceutical compositions containing them and their use in the treatment of diabetes and related diseases
DE69723869T2 (de) 1996-12-31 2004-04-22 Dr. Reddy's Laboratories Ltd. Heterozyklische verbindungen, verfahren zu ihrer herstellung, pharmazeutische zusammensetzungen die diese enthalten und ihre anwendung in der behandlung von diabetis und verwandten krankheiten
JPH11130675A (ja) * 1997-08-29 1999-05-18 Santen Pharmaceut Co Ltd クロマン誘導体含有点眼液
EP0909558A3 (en) * 1997-08-29 1999-10-27 Santen Pharmaceutical Co., Ltd. Chroman derivative containing ophthalmic solution
TWI284533B (en) * 1999-05-24 2007-08-01 Sankyo Co Pharmaceutical composition for treating hyperglycemia, impaired glucose tolerance, diabetes complications and for improving insulin resistant
JP2001039976A (ja) 1999-05-24 2001-02-13 Sankyo Co Ltd 縮合複素環化合物の塩酸塩
TW200514783A (en) 1999-09-22 2005-05-01 Bristol Myers Squibb Co Substituted acid derivatives useful as antiodiabetic and antiobesity agents and method
JP2002220336A (ja) 2000-11-22 2002-08-09 Sankyo Co Ltd 縮合複素環化合物の塩酸塩を含有する糖尿病の予防薬、治療薬
JP4090013B2 (ja) 2000-12-26 2008-05-28 第一三共株式会社 利尿剤及びインスリン抵抗性改善剤を含有する医薬組成物
KR20060118520A (ko) 2003-10-29 2006-11-23 산텐 세이야꾸 가부시키가이샤 각결막장해 치료제

Also Published As

Publication number Publication date
TWI343256B (en) 2011-06-11
CN1870997A (zh) 2006-11-29
CA2543452A1 (en) 2005-05-06
EP1679074A1 (en) 2006-07-12
TW200518750A (en) 2005-06-16
JP2005145961A (ja) 2005-06-09
ATE490771T1 (de) 2010-12-15
CY1111191T1 (el) 2015-06-11
PT1679074E (pt) 2011-03-03
SI1679074T1 (sl) 2011-04-29
US20070060628A1 (en) 2007-03-15
ES2357801T3 (es) 2011-04-29
KR20060100440A (ko) 2006-09-20
JP4217832B2 (ja) 2009-02-04
CA2543452C (en) 2012-03-13
WO2005039574A1 (ja) 2005-05-06
DE602004030470D1 (de) 2011-01-20
EP1679074B1 (en) 2010-12-08
DK1679074T3 (da) 2011-03-21
US7358255B2 (en) 2008-04-15
CN1870997B (zh) 2011-05-04
EP1679074A4 (en) 2009-03-25
WO2005039574A8 (ja) 2005-06-23
KR101154175B1 (ko) 2012-06-14

Similar Documents

Publication Publication Date Title
SI1679074T1 (sl) Terapevtsko sredstvo za keratokonjuktivno motnjo
PE20110598A1 (es) Inhibidores de las enzimas de proteina cinasa activadas por mitogeno p38
PE20090837A1 (es) Nuevos compuestos quimicos
HRP20141048T1 (hr) Spojevi, pripravci i metode
PE20051146A1 (es) Compuestos heterociclicos anticitocina
CA2634676A1 (en) Trisubstituted amine compounds as inhibitors of cholesteryl ester transfer protein cetp
PE20060243A1 (es) Derivados de 4-amino insustituido-5-(4-urea-fenil)-pirrolotriazina
PE20080951A1 (es) DERIVADOS DE 2-OXO-ETIL-AMINO-PROPIONAMIDA-PIRROLIDIN-2-IL-SUSTITUIDOS COMO INHIBIDORES DEL ENLACE DE LA PROTEINA Smac AL INHIBIDOR DE LA PROTEINA DE APOPTOSIS
PE20070004A1 (es) Imidazoquinolinas como inhibidores de quinasa de lipido
LU92166I2 (fr) Glycopyrronium ou un de ses sels
RU2008135690A (ru) Соединения и композиции в качестве ингибиторов протеинкиназы
PE20141375A1 (es) Activadores de glucoquinasa
PE20081404A1 (es) Derivados de sulfonil-fenil-2h-[1,2,4]oxadiazol-5-ona y procesos para su preparacion
PE20061373A1 (es) Composicion farmaceutica que contiene 'n-(2-cloro-6-metilfenil)-2-[[6-[4-(2-hidroxietil)-1-piperazinil]-2-metil-4-pirimidinil]amino]-5-tiazolcarboxamida
PE20090949A1 (es) Compuesto heterociclico y composicion farmaceutica del mismo
RU2008129723A (ru) Ингибиторы ccr9 активности
TW200700416A (en) 'n-(2-chloro-6-methylphenyl)-2-[[6-[4-(2-hydroxyethyl)-1-piperazinyl]-2-methyl-4-pyrimidinyl]amino]-5-thiazolecarboxamides metabolites
JP2002535394A5 (pl)
CA2473892A1 (en) Novel quinoline derivatives
HRP20120919T1 (hr) 2-[4-(pirazol-4-ilalkil)piperazin-1-il]-3-fenilpirazini i -piridini i 3-[4-(pirazol-4-ilalkil)piperazin-1-il]-2-fenilpiridini kao antagonisti receptora 5-ht7
PE20070359A1 (es) Inhibidores de pirimidinilpirazol de aurora quinasas
RU2367659C2 (ru) Гетероарильные производные в качестве активаторов рецепторов, активируемых пролифераторами пероксисом (ppar)
PE20080271A1 (es) Compuestos heterociclicos como inhibidores del transportador de glicina-1 (glyt-1)
PE20080311A1 (es) Derivados de oxadiazol como agentes afines a receptores nicotinicos
RU2010102899A (ru) Новые замещенные пиперидоны в качестве индукторов hsp